Journal article

Difficulties in Diagnosis and Treatment of 5α-Reductase Type 2 Deficiency in a Newborn with 46,XY DSD


Authors listWalter, Kerstin N.; Kienzle, Frederike B.; Frankenschmidt, Alexander; Hiort, Olaf; Wudy, Stefan A.; van der Werf-Grohmann, Natascha; Superti-Furga, Andrea; Schwab, Karl Otfried

Publication year2010

Pages67-71

JournalHormone Research in Paediatrics

Volume number74

Issue number1

ISSN1663-2818

eISSN1663-2826

DOI Linkhttps://doi.org/10.1159/000313372

PublisherKarger Publishers


Abstract
Background/Aims: Steroid 5 alpha-reductase deficiency (MIM*607306) caused by mutations in the SRD5A2 gene is characterized by a predominantly female phenotype at birth and significant virilization at puberty. The undermasculinization at birth results from low dihydrotestosterone (DHT) levels during fetal development as the type 2 isoenzyme activity is reduced. In puberty, when the type 1 isoenzyme activity increases, significant virilization occurs. Most 46,XY individuals with 5 alpha-reductase 2 deficiency develop a male gender identity. Case Report and Results: We present a case with a predominantly female phenotype and ambiguous external genitalia but a normal 46, XY karyotype. Plasma steroid analysis after beta-hCG stimulation at 8 days of age revealed a steroid profile estimated as normal with a testosterone (T)/DHT ratio of 9.5 initially misleading to the exclusion of 5 alpha-reductase deficiency. However, mutation analysis of the SRD5A2 gene revealed a homozygote point mutation (Leu55Gln) confirming the diagnosis of 5 alpha-reductase deficiency. A male phenotype was successfully achieved by hormone treatment with T and DHT after diagnosing 5 alpha-reductase deficiency and a masculinization operation. As a side effect skeletal age accelerated temporarily. Conclusion: In individuals with predominantly female phenotype and suspected 5 alpha-reductase deficiency, a T/DHT ratio during the neonatal period >8.5 might point to 5 alpha-reductase deficiency. After confirmation of the diagnosis by molecular analysis of the SRD5A2 gene, a satisfactory change to a male phenotype can be achieved by hormone treatment preceding surgery. Copyright (C) 2010 S. Karger AG, Basel



Citation Styles

Harvard Citation styleWalter, K., Kienzle, F., Frankenschmidt, A., Hiort, O., Wudy, S., van der Werf-Grohmann, N., et al. (2010) Difficulties in Diagnosis and Treatment of 5α-Reductase Type 2 Deficiency in a Newborn with 46,XY DSD, Hormone Research in Paediatrics, 74(1), pp. 67-71. https://doi.org/10.1159/000313372

APA Citation styleWalter, K., Kienzle, F., Frankenschmidt, A., Hiort, O., Wudy, S., van der Werf-Grohmann, N., Superti-Furga, A., & Schwab, K. (2010). Difficulties in Diagnosis and Treatment of 5α-Reductase Type 2 Deficiency in a Newborn with 46,XY DSD. Hormone Research in Paediatrics. 74(1), 67-71. https://doi.org/10.1159/000313372



Keywords


46,XY DSD5 alpha-reductase deficiencyAmbiguous genitaliaGENDER IDENTITYMALE PSEUDOHERMAPHRODITISMSRD5A1 gene mutationSRD5A2 gene mutationTestosterone/dihydrotestosterone ratio

Last updated on 2025-21-05 at 18:43